Retifanlimab FDA approval date

The FDA approved Retifanlimab (INCMGA00012) on 22 Mar 2023.

FDA approval date
22 Mar 2023

Drug identity checked against registry records

Also recorded as INCMGA00012; MGA012; Zynyz

Included trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2023-03-22DayRetifanlimabFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761334", "applicant_as_listed_by_fda": "INCYTE CORP", "brand_names": ["ZYNYZ"], "active_ingredients": ["RETIFANLIMAB-DLWR"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230322", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026